Nonalcoholic Steatohepatitis Will Pose Clinical, Economic Burden

TUESDAY, Jan. 14, 2020 -- Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S. patients with type 2 diabetes mellitus (T2DM), according to a study published online Jan....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news